ストックスクリーナーアプリを入手
0.8435
0.78%
-0.0065
前日終値:
$0.85
開ける：
$0.85
24時間の取引高:
93,648
Relative Volume:
0.20
時価総額：
$56.62M
収益：
-
当期純損益:
$-46.12M
株価収益率:
-0.976
EPS:
-0.8642
ネットキャッシュフロー:
$-41.02M
1週間 パフォーマンス:
-5.79%
1か月 パフォーマンス:
+9.55%
6か月 パフォーマンス:
-66.80%
1年 パフォーマンス:
-46.96%
1日の値動き範囲:
$0.82
$0.865
1週間の範囲:
$0.80
$0.93
52週間の値動き範囲:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
IFRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.8434 | 60.57M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.75 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.69 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.57 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.26 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-02-28 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-06 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-04-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-06-05 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2019-06-05 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-01-29 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-10 | 開始されました | Credit Suisse | Outperform |
| 2018-07-13 | 開始されました | BMO Capital Markets | Outperform |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-28 | 開始されました | SunTrust | Buy |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Inflarx N V (IFRX) 最新ニュース
why inflarx n.v. stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
Why InflaRx N.V. stock attracts strong analyst attentionShort Term High Return Strategy - Newser
What makes InflaRx N.V. stock price move sharplyMarket Trend Watch - Newser
InflaRx Receives Nasdaq Deficiency Notice for Share Price - TipRanks
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
InflaRx receives nasdaq notice for minimum bid price requirement By Investing.com - Investing.com Nigeria
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - AInvest
InflaRx receives nasdaq notice for minimum bid price requirement - Investing.com India
InflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Requirement - Nasdaq
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
InflaRx Faces Critical 180-Day Window to Meet Nasdaq $1 Minimum Bid Requirement - Stock Titan
InflaRx (NASDAQ:IFRX) Shares Up 2.1% – Here’s Why - Defense World
InflaRx Appoints KPMG as New Auditor Following Shareholder Approval - TipRanks
Analyzing InflaRx (NASDAQ:IFRX) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World
Brokers Offer Predictions for InflaRx FY2026 Earnings - Defense World
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events - The Globe and Mail
InflaRx (NASDAQ:IFRX) Short Interest Update - Defense World
InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World
InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria
InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus
IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com
Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Inflarx drops lead program targeting C5a in rare skin disorder - biocentury.com
Top Midday Decliners - marketscreener.com
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga
Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com Nigeria
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
PG rating: Inflarx review declares phase III bomb - BioWorld MedTech
InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus
InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com
InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus
InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire
Clinical Trial Setback: InflaRx Discontinues Key Drug Program After Phase 3 Futility Results - Stock Titan
InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World
InflaRx to Participate in Upcoming Investor Conferences - The Manila Times
InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan
Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World
Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Inflarx N V (IFRX) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
2.49%
大文字化:
|
ボリューム (24 時間):